Suggested remit: To appraise the clinical and cost effectiveness of glofitamab with gemcitabine and oxaliplatin within its marketing authorisation for treating relapsed or refractory diffuse large B-cell lymphoma.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6202

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
26 July 2024 Please note that following on from information received from the company this appraisal has been rescheduled to align with latest regulatory expectations and the appraisal is now anticipated to begin in late November 2024.
19 March 2024 - 18 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6202
19 March 2024 In progress. Scoping commenced.
08 February 2024 Please note that following on from information received from the company, the timelines for this appraisal have now been revised and the appraisal is now anticipated to begin in late July 2024.
16 October 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-June 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
25 October 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual